Barr metformin tentative ANDA revoked
Executive Summary
FDA withdraws Barr's tentative approval for metformin extended-release (Bristol-Myers Squibb's Glucophage XR) because of concerns with raw material supplied by Ivax-owned API (formerly ChemSource). Barr expects to select a new raw materials supplier. Ivax markets generic metformin under 180-day exclusivity, splitting profits with Purepac (1"The Pink Sheet" Dec. 1, 2003, p. 17). Par is also on the market with an "authorized" metformin generic...
You may also be interested in...
Glucophage XR Settlement: Purepac, Ivax Split Generic Profits For 180 Days
Ivax and Purepac's exclusivity rights settlement for a generic version of Glucophage XR means FDA has avoided a legal challenge to its interpretation of first-to-file requirements for new ANDAs compared to amended applications
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.